利司那肽(早餐前或主餐前注射)改善2型糖尿病全天血糖谱:来自于动态血糖监测的分析  

Diurnal Glucose Exposure Profiles of Patients Treated with Lixisenatide before Breakfast or the Main Meal of the Day: an Analysis Using Continuous Glucose Monitoring

作　　者：毕艳[1] BI Yan(Department of Endocrinology, Nanjing Drum Tower Hospital, Nanjing Jiangsu 210008, China)

机构地区：[1]南京鼓楼医院内分泌科,江苏南京210008

出　　处：《药品评价》2019年第7期17-20,22,共5页Drug Evaluation

摘　　要：进餐后的血糖波动是2型糖尿病患者服用降糖药后血糖不达标的原因之一。近期研究发现,新型胰高糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂——利司那肽能改善服用二甲双胍血糖控制不佳患者的糖化血红蛋白(glycatedhemoglobin,HbA1c)。通过动态血糖监测(continuous glucose monitoring,CGM)发现,利司那肽两种给药时间,一是早餐前注射(早餐可能不是全天的主餐),第二种是全天的主餐前注射,降糖效果相当,均可减少餐后血糖波动。本文对2017年5月发表在Diabetes Metabolism Research And Reviews杂志上的文章"利司那肽(早餐前或主餐前注射)改善2型糖尿病全天血糖谱:来自于动态血糖监测的分析"进行中文摘译。同时,特邀李小英教授对此文做一点评。Postprandial plasma glucose excursions of the day contributes to glucose targeting failure for type 2 diabetes previously treated with different oral anti-diabetic drugs(OAD). Recent study had found that a novel glucagon-like peptide-1 agonist--Lixisenatide is another choice for the patients uncontrolled by metformin. Lixisenatide therapy before breakfast or the main meal of the day could further improved glycated hemoglobin(HbA1 c) and postprandial glucose excursions for diabetes uncontrolled by metformin. This article provided simple translation for the research article titled with "Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: an analysis using continuous glucose monitoring"(published in Diabetes Metabolism Research And Reviews, 2017 May;33(4). doi: 10.1002/dmrr.2879. Epub 2017 Feb 28) and opinion by invited LI Xiao ying Rrofessor.

关 键 词：动态血糖监测 胰高糖素样肽-1 糖化血红蛋白 餐后血糖 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]